Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 40Triple Negative Breast Neoplasms 34Carcinoma, Non-Small-Cell Lung 11Carcinoma, Transitional Cell 10Urinary Bladder Neoplasms 9Neoplasm Metastasis 8Lung Neoplasms 5Brain Neoplasms 5Endometrial Neoplasms 4Small Cell Lung Carcinoma 3Ovarian Neoplasms 3Glioblastoma 3Uterine Cervical Neoplasms 2Salivary Gland Neoplasms 2Pancreatic Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Ovarian Epithelial 2Advanced Breast Cancer 2Uterine Neoplasms 1Urothelial Bladder Carcinoma 1Triple Negative Locally Advanced Non-resectable Breast Cancer 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1

Interventions

Injections 27Carboplatin 18Docetaxel 14pembrolizumab 13Paclitaxel 12Bevacizumab 10durvalumab 8Nivolumab 8Cisplatin 8Fluorouracil 7Pemetrexed 6Oxaliplatin 6Leucovorin 6trifluridine tipiracil drug combination 5toripalimab 5tislelizumab 5linifanib 5Capecitabine 5zimberelimab 4talazoparib 4olaparib 4fludarabine 4Panobinostat 4Itraconazole 4Irinotecan 4Gemcitabine 4Everolimus 4tremelimumab 3sotorasib 3sintilimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Solid Tumors × sacituzumab govitecan × Clear all
NCT06167317 2026-05-28

Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

Gilead Sciences

Phase 1 Recruiting
278 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡